News › Clinical Practice, Industry News, News

Revance & Mylan to Advance Development Program for Biosimilar to Botox

June 2, 2020

Revance Therapeutics, Inc. and Mylan N.V. has announced Mylan’s decision to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to Botox and Botox Cosmetic (onabotulinumtoxinA), the market-leading neuromodulator.Feedback obtained from the U.S. Food and Drug Administration (FDA) during a Biosimilar Initial Advisory Meeting (BIAM) held in February 2019 indicated that the 351(k) regulatory pathway for an onabotulinumtoxinA product is viable. Based on this meeting, along with the results from additional characterization and analysis completed by Revance, the two companies are now moving forward with the development program.Read more at Business Wire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • AmSpa CEO Reflects on the Sonya Dakar Case
    • SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
    • GlossGenius Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • FDA Advisory Committee to Review Seven Peptides for Potential Use in Compounding
    • PDGF, Regenerative Medicine and the Questions Med Spas Can’t Ignore
Advertisement